Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Elicio Therapeutics Inc (ELTX)

Elicio Therapeutics Inc (ELTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 91,883
  • Shares Outstanding, K 10,232
  • Annual Sales, $ 0 K
  • Annual Income, $ -35,200 K
  • 60-Month Beta 0.70
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 6.65
Trade ELTX with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/24
See More
  • Average Estimate -1.09
  • Number of Estimates 2
  • High Estimate -0.97
  • Low Estimate -1.21
  • Prior Year -1.50
  • Growth Rate Est. (year over year) +27.33%

Price Performance

See More
Period Period Low Period High Performance
1-Month
7.28 +23.35%
on 04/04/24
10.44 -13.96%
on 04/15/24
+1.61 (+21.85%)
since 04/03/24
3-Month
2.96 +203.38%
on 02/07/24
10.44 -13.96%
on 04/15/24
+4.58 (+104.09%)
since 02/02/24
52-Week
2.96 +203.38%
on 02/07/24
24.39 -63.18%
on 06/02/23
+2.20 (+32.49%)
since 05/03/23

Most Recent Stories

More News
Elicio Therapeutics Celebrates 13 Years Developing Innovative Cancer Immunotherapies

Boston, Massachusetts () April 24, 2024 -- Elicio Therapeutics, a clinical biotechnology company, commemorates its 13th anniversary of innovative medical research into cancer vaccines.

ELTX : 8.98 (-0.22%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Buy with a Average short term outlook on maintaining the current direction.

See More Share

Business Summary

Elicio Therapeutics is a privately-held clinical-stage biotechnology company. It involved in developing a pipeline of novel immunotherapies for the treatment of cancer and other diseases. Elicio Therapeutics, formerly known as Angion Biomedica Corp, is based in BOSTON.

See More

Key Turning Points

3rd Resistance Point 10.55
2nd Resistance Point 10.17
1st Resistance Point 9.57
Last Price 8.98
1st Support Level 8.59
2nd Support Level 8.21
3rd Support Level 7.61

See More

52-Week High 24.39
Fibonacci 61.8% 16.20
Fibonacci 50% 13.67
Fibonacci 38.2% 11.15
Last Price 8.98
52-Week Low 2.96

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar